Nanomedicine and precision bacteriotherapy

NanoXomics builds translational platforms for high-burden microbial and metabolic disease.

Two lead programs, Nebucage and Oxalytic, pair mechanism-driven science with practical commercialization paths: device coatings for biofilm prevention and biomarker-enabled microbiome products for oxalate metabolism.

Explore Nebucage Explore Oxalytic

Company focus

From bench-validated biology to partnership-ready products.

NanoXomics is advancing two differentiated assets from founder-led research: a bimetallic antimicrobial nanoparticle coating for urologic devices and a defined, multi-strain microbiome approach for oxalate-driven disease.

The work is designed for clear endpoints, scalable manufacturing, and staged market entry through device manufacturer partnerships, supplement-first launch options, and future therapeutic expansion.

6-7 log uropathogen reduction shown in Nebucage materials

$0.01 estimated material cost per catheter

Multi-strain defined Oxalytic human commensal consortium

24h urinary oxalate as a measurable clinical biomarker

Lead program 01

Nebucage: antimicrobial nanotechnology for urologic device biofilms.

Fullerene-coated gold-silver nanoparticles designed to prevent and reduce bacterial colonization on catheters, stents, and other indwelling urologic devices.

Nebucage nanoparticle concept with urologic devices and bacteria

Why it matters

Biofilms are a persistent healthcare challenge. NanoXomics materials cite near-universal colonization of long-term urologic devices and limited protection from antibiotic-based coatings.

Mechanism

Reactive oxygen species generation targets bacterial DNA, proteins, and lipids through a multi-pronged antimicrobial effect.

Performance

Studies report 100% reduction of key uropathogens at physiologically relevant concentrations (Rodriguez-Alvarez et al. Scientific Reports 2026).

Manufacturing

Single-step, green aqueous synthesis at ambient conditions supports cost-efficient scale-up.

Lead program 02

Oxalytic: precision microbiome for oxalate-driven diseases.

A defined multi-strain human commensal consortium paired with an oxc/frc qPCR response biomarker for targeted deployment in kidney stone disease, hyperoxaluria, CKD risk, and adjacent metabolic indications.

Oxalytic solution slide showing multi-strain blend, predictive biomarker, and preclinical validation

Precision, not commodity probiotics

Oxalytic is built around the premise that oxalate homeostasis depends on microbial network function, and that baseline oxalate-degrading gene abundance can help identify likely responders.

Consortium

Diverse oxalate-degrading commensals provide redundancy across oxalate-degrading microbial networks (Mukherjee et al. eLife 2025).

Biomarker

Baseline oxc/frc gene abundance enables stratification and a niche-filling response model (Suryavanshi et al. Gut Microbes 2025).

Path

Supplement-first commercialization can generate early revenue and real-world evidence while de-risking a live biotherapeutic path.

Evidence and differentiation

Built for partners who need a clear scientific and commercial rationale.

Nebucage proof points

Strong IP protection around structure and antimicrobial applications, non-antibiotic mechanism, low material cost, and a licensing model for device manufacturers.

Oxalytic proof points

Patent-pending. Defined strains, predictive biomarker strategy, preclinical efficacy signals, and staged supplement-to-LBP development path.

Recent publications

Rodriguez-Alvarez et al. Scientific Reports 2026; Suryavanshi et al., Gut Microbes 2025; Suryavanshi et al., npj Biofilms and Microbiomes 2026; Mukherjee et al., eLife 2025.

Partner fit

Designed for medical device companies, microbiome investors, strategic health partners, and translational grant or accelerator programs.

Development view

Two platforms, staged for practical translation.

Program Modality Lead use Commercial route

Nebucage Bimetallic nanoparticle coating Urologic device biofilm prevention Strategic partnership or licensing

Oxalytic Multi-strain precision bacteriotherapy Oxalate metabolism and kidney stone recurrence risk Supplement-first, future IND expansion

Team

World-class expertise in microbiome and nanomedicine.

NanoXomics is led by translational researchers and clinical experts spanning microbial sciences, biomedical engineering, urology, medical devices, and oxalate-driven disease biology.